CollPlant Biotechnologies (CLGN) Cash & Equivalents (2017 - 2025)

CollPlant Biotechnologies (CLGN) has 9 years of Cash & Equivalents data on file, last reported at $5.6 million in Q4 2025.

• Quarterly Cash & Equivalents fell 53.05% year-over-year to $5.6 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $5.6 million (down 53.05% YoY) and the FY2025 annual result came in at $5.6 million, down 53.05% from the prior year.
• Cash & Equivalents fell to $5.6 million in Q4 2025, from $11.4 million in the prior quarter.
• In the past five years, Cash & Equivalents ranged from a high of $41.3 million in Q1 2022 to a low of $5.6 million in Q4 2025.
• A 5-year average of $23.1 million and a median of $24.1 million in 2021 frame the typical range for Cash & Equivalents.
• Annual changes were most pronounced in 2021 — Cash & Equivalents surged 411.42% — and 2024, when it tumbled 55.35%.
• Tracing CLGN's Cash & Equivalents over 5 years: stood at $13.4 million in 2021, then jumped by 123.3% to $29.9 million in 2022, then dropped by 10.68% to $26.7 million in 2023, then plunged by 55.35% to $11.9 million in 2024, then slumped by 53.05% to $5.6 million in 2025.
• The last three Cash & Equivalents figures came in at $5.6 million (Q4 2025), $11.4 million (Q2 2025), and $11.9 million (Q4 2024), per Business Quant data.